The scholarship will pay for 4 years of tuition, fees and books at an Indiana public or private nonprofit college or ...

We recently compiled a list of the Jim Cramer’s Bold Predictions About These 10 Healthcare Stocks. In this article, we are ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

Kennedy Jr., President-elect Donald Trump’s nominee to head the US Department of Health and Human Services, who has expressed reservations about the pharma industry — and its new wonder drug category.

The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After ...

INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to ...

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, ...

Encouraging primary care physicians to screen patients for physical inactivity with a simple questionnaire can help identify ...

Experts propose potential workarounds for obstacles to wider use of combined clinics and personalized medicine for ...

Eli Lilly has signed another bolt-on deal to bulk ... new medicines for people struggling with chronic pain,” said the company’s head of pain and neurodegeneration research Mark Mintun.

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.

Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking ...